Cwm LLC Grows Position in Repligen Co. (NASDAQ:RGEN)

Cwm LLC increased its position in shares of Repligen Co. (NASDAQ:RGEN) by 36.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 428 shares of the biotechnology company’s stock after buying an additional 114 shares during the quarter. Cwm LLC’s holdings in Repligen were worth $64,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in RGEN. Andra AP fonden acquired a new stake in Repligen during the 2nd quarter worth approximately $25,000. Lazard Asset Management LLC lifted its position in Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 136 shares during the period. International Assets Investment Management LLC acquired a new stake in Repligen during the 2nd quarter worth approximately $33,000. Rothschild Investment LLC acquired a new stake in Repligen during the 2nd quarter worth approximately $57,000. Finally, GAMMA Investing LLC lifted its position in Repligen by 183.4% during the 2nd quarter. GAMMA Investing LLC now owns 479 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 310 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on RGEN shares. Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 31st. UBS Group dropped their price target on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Wells Fargo & Company started coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Stock Up 0.2 %

NASDAQ:RGEN opened at $135.45 on Monday. The firm has a market capitalization of $7.57 billion, a PE ratio of 541.80, a price-to-earnings-growth ratio of 4.16 and a beta of 0.95. The stock has a 50 day moving average of $143.45 and a 200-day moving average of $147.04. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business had revenue of $154.07 million during the quarter, compared to analyst estimates of $154.11 million. During the same period in the prior year, the company posted $0.53 EPS. The business’s revenue for the quarter was down 3.2% compared to the same quarter last year. Analysts predict that Repligen Co. will post 1.45 EPS for the current year.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.